Scleroderma Therapeutics Market, Size, Share, Opportunities and Forecast, 2020-2027

SKU: DHC275 | Last Updated On: Jun 09 2020 | No. of Pages: 181 | Available Formats

> Global Scleroderma Therapeutics Market Expected to reach a high CAGR of 5.89% By 2027: DataM Intelligence

Global Scleroderma Therapeutics Market is segmented By Drug Class (Immunosuppressors, Phosphodiesterase 5 Inhibitors – PHA, Endothelin Receptor Antagonists (ERA), Prostacyclin Analogues (PA), Calcium Channel Blockers (CCBs), Analgesics, Others), By Indication (Systemic, Localized), By Distribution Channel (Retail Stores, Online Stores, Hospitals, Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2020-2027

 

Market Overview

The Global Scleroderma Therapeutics Market is expected to grow at a CAGR of 5.89% during the forecasting period (2020-2027).

Scleroderma, or systemic sclerosis, is a chronic connective tissue disease generally classified as one of the autoimmune rheumatic diseases. It causes tissue throughout the body, including the lungs and other organs, to thicken and scar. SSc-ILD is a progressive lung disease in which lung function declines over time, and it can be debilitating and life-threatening. ILD is the leading cause of death among people with scleroderma, typically resulting from a loss of pulmonary function that occurs when the lungs cannot supply enough oxygen to the heart. Scleroderma is majorly of two types: localized scleroderma and systemic sclerosis (SSc).

Market Overview

 

Source: DataM Intelligence Analysis (2019)

Market Dynamics

The global scleroderma therapeutics market growth is driven by several factors such as rising prevalence of scleroderma, increasing screening rates of scleroderma, and growing research & development activities for drug discovery to treat the scleroderma.

In the United States, the prevalence of scleroderma is 240 per million and an annual incidence of 19 per million. In Europe, the prevalence of scleroderma is estimated to be between 10 and 150 per million people, while the annual incidence has been reported to be between 3 and 28 per million people. Women are four times more prone to develop systemic scleroderma than men. The incidence of systemic sclerosis is higher in African American patients, than in non-African American patients. Among all African Americans, 23.7 people per million are diagnosed with systemic sclerosis, while the comparable rate among non-African Americans is 18.3 people per million diagnosed.  The prevalence of 315 of every one million African Americans diagnosed with systemic sclerosis while, 225 of every one million non-African Americans are diagnosed with systemic sclerosis. Hence, with rising prevalence of scleroderma, the demand for its treatment is increasing, thus boosting the growth of the market globally.

In addition, the emergence of new drugs in clinical trial phases is expected to boost the growth of the market during the forecast period. For instance, in August 2019, Emerald Health Pharmaceuticals Inc. (EHP), completed its Phase I clinical trial evaluating the safety, pharmacokinetics, pharmacodynamics and exploratory biomarkers of its lead product candidate, EHP-101, an oral formulation of a patented new chemical entity (NCE) derived from cannabidiol (CBD) for the treatment of multiple sclerosis (MS) and systemic scleroderma (SSc) patients. Start-up activities are underway for the initiation of Phase II clinical studies of EHP-101 in MS and SSc patients, with initiation of the first Phase II study expected by the end of 2019.

Also, in April 2019, Vicore Pharma AB has selected diffuse systemic sclerosis (dSSc) as the second indication for its lead program VP01 (C21), which complements the primary indication, idiopathic pulmonary fibrosis (IPF). Diffuse systemic sclerosis has strong involvement of angiotensin II and an upregulation of the angiotensin II type 2 receptor (AT2R – the C21 target), which is known to mediate anti-fibrotic as well as vascular effects within a number of disease models. VP01 is currently being explored within a prolonged phase I study for dose optimization. Both IIa phase studies are expected to begin in the second half of 2019.

However, the scleroderma treatment market growth is expected to hinder by some factors including lack of curative treatment, poor efficacy and efficiency of present drug regimens.

Market Segmentation

By indication, the global scleroderma therapeutics market is segmented into systemic and localized scleroderma. Among these, systemic indication segment expected to hold the largest share over the forecast period, owing to use of high-priced immunosuppressants. Several indications such as SSc-induced symptoms and conditions that range from interstitial lung disease to pulmonary arterial hypertension fall under systemic scleroderma. In September 2019, the U.S. FDA approved Ofev (nintedanib) capsules to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or scleroderma, called SSc-ILD.

On the other hand, localized scleroderma is estimated to grow at the fastest CAGR during the forecast period. There are several drugs in the pipeline for localized scleroderma which are expected to launch including FCX-013 by Fibrocell. Fibrocell’s FCX-013 holds orphan drug and fast track designation and if approved, it would be the first gene therapy for localized scleroderma. Also, Lenabasum by Corbus Pharmaceuticals is the first oral therapy with high therapeutic potential targeting diffuse cutaneous systemic sclerosis.

On the basis of drug class, the market is segmented into immunosuppressors, Phosphodiesterase 5 inhibitors – PHA, endothelin receptor antagonists (ERA), prostacyclin analogues (PA), calcium channel blockers (CCBs), analgesics, and others. Among these, the immunosuppressors drug class accounted for the largest market share in 2018, and expected to show dominance over the forecast period, as this drug class has several biologics from major players.

Source: DataM Intelligence Analysis (2019)

Geographical Analysis

North America in dominating the global scleroderma therapeutics market accounted for the largest market share in 2018, owing to presence of recently developed immunosuppressants along with favorable reimbursement scenario. The estimated incidence of systemic sclerosis in the United States is 20 cases per million population, and its prevalence has been estimated at 276 cases per million population. An increased systemic sclerosis incidence and prevalence has been evident in the last 50 years. Although improved diagnosis and increased survival rate can partially account for this observation, it appears that there has been a real increase in its incidence. In addition, presence of favorable government regulations and funding programs along with increasing clinical trials to enhance the efficiency and new product development are also some of the factors driving the growth of the market in this region over the forecast period.

Asia Pacific scleroderma therapeutics market is growing at the fastest growth rate during the forecast period, due to rising incidence of scleroderma, large number of unmet patient needs and rising demand for the treatment. In countries such as Japan and Australia generics and OTC drugs are the mainstay therapy for scleroderma and its symptoms. The Japan market although experiencing price cuts has faster access to new orphan therapies. Expected increase in access to biosimilar and generic immunosuppressants are estimated to drive the market growth in this region.

Competitive Landscape

The market is highly fragmented with presence of large number of players. Some of the major players in the market include: Boehringer Ingelheim International GmbH, Corbus Pharmaceuticals Holdings, Inc., Bayer AG, Gilead Sciences, Inc., Allergan, Inc., Pfizer, Inc., Sanofi, GlaxoSmithKline plc, Cumberland Pharmaceuticals, Inc., Actelion Pharmaceuticals, Inc., among others.

The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations which are contributing to the growth of the scleroderma therapeutics market globally. For instance,

In May 2019, Corbus Pharmaceuticals Holdings, Inc. completed a Phase 3 study assessing the efficacy and safety of lenabasum for the treatment of systemic sclerosis (SSc). The Company expects to report topline results from this study by 2020.

In January 2019, Gemelli Biotech launched a blood test, called Sclero-smart, the first and only commercially available test that measures anti-vinculin levels to help physicians identify the risk of gastrointestinal or vascular complications among patients with scleroderma and systemic sclerosis.

Why Purchase the Report?

  • Visualize the composition of the scleroderma therapeutics market segmentation by drug class, indication, and distribution channel highlighting the key commercial assets and players.

  • Identify commercial opportunities in scleroderma therapeutics market by analyzing trends and co-development deals.

  • Excel data sheet with thousands of data points of scleroderma therapeutics market - level 4/5 segmentation.

  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

  • Product mapping in excel for the key product of all major market players

The global scleroderma therapeutics market report would provide an access to an approx. 54 market data table, 50 figures and 190 pages.

Target Audience

  • Service Providers/ Buyers

  • Industry Investors/Investment Bankers

  • Education & Research Institutes

  • Research Professionals

  • Emerging Companies

  • Manufacturers

 

Related Reports

Xerostomia Therapeutics Market

Melanoma Therapeutics Market

 

 

 

Table of Con​​​​​​​tent

  1. Scleroderma Therapeutics Market Methodology and Scope

    1. Research Methodology
    2. Research Objective and Scope of the Report
  2. Scleroderma Therapeutics Market – Market Definition and Overview

  3. Scleroderma Therapeutics Market – Executive Summary

    1. Market Snippet by Drug Class
    2. Market Snippet by Indication
    3. Market Snippet by Distribution Channel
    4. Market Snippet by Region
  4. Scleroderma Therapeutics Market Dynamics

    1. Market Impacting Factors
    2. Drivers
      1. Rising incidence of scleroderma
      2. Growing research & development activities
    3. Restraints
      1. Lack of curative treatment
    4. Opportunity
    5. Impact Analysis
  5. Scleroderma Therapeutics Market – Industry Analysis

    1. Porter's Five Forces Analysis
    2. Epidemiology
    3. Regulatory Analysis
    4. Supply Chain Analysis
    5. Product Innovations
    6. Unmet Needs
  6. Scleroderma Therapeutics Market – By Drug Class

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment
      2. Market Attractiveness Index, By Drug Class Segment
    2. Immunosuppressors*
      1. Introduction
      2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    3. Phosphodiesterase 5 Inhibitors - PHA
    4. Endothelin Receptor Antagonists (ERA)
    5. Prostacyclin Analogues (PA)
    6. Calcium Channel Blockers (CCBs)
    7. Analgesics
    8. Others
  7. Scleroderma Therapeutics Market – By Indication

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Segment
      2. Market Attractiveness Index, By Indication Segment
    2. Systemic*
      1. Introduction
      2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    3. Localized
  8. Scleroderma Therapeutics Market – By Distribution Channel

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
      2. Market Attractiveness Index, By Distribution Channel Segment
    2. Retail Stores*
      1. Introduction
      2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    3. Online Stores
    4. Hospitals
    5. Others
  9. Scleroderma Therapeutics Market – By Region

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
      2. Market Attractiveness Index, By Region
    2. North America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. U.S.
        2. Canada
        3. Mexico
    3. Europe
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Germany
        2. U.K.
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe
    4. South America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Brazil
        2. Argentina
        3. Rest of South America
    5. Asia Pacific
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. China
        2. India
        3. Japan
        4. Australia
        5. Rest of Asia Pacific
    6. Middle East and Africa
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  10. Scleroderma Therapeutics Market – Competitive Landscape

    1. Competitive Scenario
    2. Market Positioning/Share Analysis
    3. Mergers and Acquisitions Analysis
  11. Scleroderma Therapeutics Market- Company Profiles

    1. Boehringer Ingelheim International GmbH*
      1. Company Overview
      2. Product Portfolio and Description
      3. Key Highlights
      4. Financial Overview
    2. Corbus Pharmaceuticals Holdings, Inc.
    3. Bayer AG
    4. Gilead Sciences, Inc.
    5. Allergan, Inc.
    6. Pfizer, Inc.
    7. Sanofi
    8. GlaxoSmithKline plc
    9. Cumberland Pharmaceuticals, Inc.
    10. Actelion Pharmaceuticals, Inc. (List Not Exhaustive)
  12. Scleroderma Therapeutics Market – Premium Insights

  13. Scleroderma Therapeutics Market – DataM

    1. Appendix
    2. About Us and Services
    3. Contact Us

List of Tables and Figures

List of Tables

Table 1 Global Scleroderma Therapeutics Market Value, By Drug Class, 2018,2022 & 2027 ($ Million)

Table 2 Global Scleroderma Therapeutics Market Value, By Indication, 2018,2022 & 2027 ($ Million)

Table 3 Global Scleroderma Therapeutics Market Value, By Distribution Channel, 2018,2022 & 2027 ($ Million)

Table 4 Global Scleroderma Therapeutics Market Value, By Drug Class, 2018,2022 & 2027 ($ Million)

Table 5 Global Scleroderma Therapeutics Market Value, By Drug Class, 2017-2027 ($ Million)

Table 6 Global Scleroderma Therapeutics Market Value, By Indication, 2018,2022 & 2027 ($ Million)

Table 7 Global Scleroderma Therapeutics Market Value, By Indication, 2017-2027 ($ Million)

Table 8 Global Scleroderma Therapeutics Market Value, By Distribution Channel, 2018,2022 & 2027 ($ Million)

Table 9 Global Scleroderma Therapeutics Market Value, By Distribution Channel, 2017-2027 ($ Million)

Table 10 North America Scleroderma Therapeutics Market Value, By Drug Class, 2017-2027 ($ Million)

Table 11 North America Scleroderma Therapeutics Market Value, By Indication, 2017-2027 ($ Million)

Table 12 North America Scleroderma Therapeutics Market Value, By Distribution Channel, 2017-2027 ($ Million)

Table 13 South America Scleroderma Therapeutics Market Value, By Drug Class, 2017-2027 ($ Million)

Table 14 South America Scleroderma Therapeutics Market Value, By Indication, 2017-2027 ($ Million)

Table 15 South America Scleroderma Therapeutics Market Value, By Distribution Channel, 2017-2027 ($ Million)

Table 16 Europe Scleroderma Therapeutics Market Value, By Drug Class, 2017-2027 ($ Million)

Table 17 Europe Scleroderma Therapeutics Market Value, By Indication, 2017-2027 ($ Million)

Table 18 Europe Scleroderma Therapeutics Market Value, By Distribution Channel, 2017-2027 ($ Million)

Table 19 Asia-Pacific Scleroderma Therapeutics Market Value, By Drug Class, 2017-2027 ($ Million)

Table 20 Asia-Pacific Scleroderma Therapeutics Market Value, By Indication, 2017-2027 ($ Million)

Table 21 Asia-Pacific Scleroderma Therapeutics Market Value, By Distribution Channel, 2017-2027 ($ Million)

Table 22 Middle East & Africa Scleroderma Therapeutics Market Value, By Drug Class, 2017-2027 ($ Million)

Table 23 Middle East & Africa Scleroderma Therapeutics Market Value, By Indication, 2017-2027 ($ Million)

Table 24 Middle East & Africa Scleroderma Therapeutics Market Value, By Distribution Channel, 2017-2027 ($ Million)

Table 25 Boehringer Ingelheim International GmbH: Overview

Table 26 Boehringer Ingelheim International GmbH: Product Portfolio

Table 27 Boehringer Ingelheim International GmbH: Key Developments

Table 28 Corbus Pharmaceuticals Holdings, Inc.: Overview

Table 29 Corbus Pharmaceuticals Holdings, Inc.: Product Portfolio

Table 30 Corbus Pharmaceuticals Holdings, Inc.: Key Developments

Table 31 Bayer AG: Overview

Table 32 Bayer AG: Product Portfolio

Table 33 Bayer AG: Key Developments

Table 34 Gilead Sciences, Inc.: Overview

Table 35 Gilead Sciences, Inc.: Product Portfolio

Table 36 Gilead Sciences, Inc.: Key Developments

Table 37 Allergan, Inc.: Overview

Table 38 Allergan, Inc.: Product Portfolio

Table 39 Allergan, Inc.: Key Developments

Table 40 Pfizer, Inc.: Overview

Table 41 Pfizer, Inc.: Product Portfolio

Table 42 Pfizer, Inc.: Key Developments

Table 43 Sanofi: Overview

Table 44 Sanofi: Product Portfolio

Table 45 Sanofi: Key Developments

Table 46 GlaxoSmithKline plc: Overview

Table 47 GlaxoSmithKline plc: Product Portfolio

Table 48 GlaxoSmithKline plc: Key Developments

Table 49 Cumberland Pharmaceuticals, Inc.: Overview

Table 50 Cumberland Pharmaceuticals, Inc.: Product Portfolio

Table 51 Cumberland Pharmaceuticals, Inc.: Key Developments

Table 52 Actelion Pharmaceuticals, Inc.: Overview

Table 53 Actelion Pharmaceuticals, Inc.: Product Portfolio

Table 54 Actelion Pharmaceuticals, Inc.: Key Developments

 List of Figures

Figure 1 Global Scleroderma Therapeutics Market Share, By Drug Class, 2018 & 2027 (%)

Figure 2 Global Scleroderma Therapeutics Market Share, By Indication, 2018 & 2027 (%)

Figure 3 Global Scleroderma Therapeutics Market Share, By Distribution Channel, 2018 & 2027 (%)

Figure 4 Global Scleroderma Therapeutics Market Value, 2017-2027 ($ Million)

Figure 5 Global Scleroderma Therapeutics Market Y-o-Y Growth, By Drug Class, 2018-2027 (%)

Figure 6 Immunosuppressors: Global Scleroderma Therapeutics Market Value, 2017-2027 ($ Million)

Figure 7 Phosphodiesterase 5 Inhibitors - PHA: Global Scleroderma Therapeutics Market Value, 2017-2027 ($ Million)

Figure 8 Endothelin Receptor Antagonists (ERA): Global Scleroderma Therapeutics Market Value, 2017-2027 ($ Million)

Figure 9 Prostacyclin Analogues (PA): Global Scleroderma Therapeutics Market Value, 2017-2027 ($ Million)

Figure 10 Calcium Channel Blockers (CCBs): Global Scleroderma Therapeutics Market Value, 2017-2027 ($ Million)

Figure 11 Analgesics: Global Scleroderma Therapeutics Market Value, 2017-2027 ($ Million)

Figure 12 Others: Global Scleroderma Therapeutics Market Value, 2017-2027 ($ Million)

Figure 13 Global Scleroderma Therapeutics Market Y-o-Y Growth, By Indication, 2018-2027 (%)

Figure 14 Systemic: Global Scleroderma Therapeutics Market Value, 2017-2027 ($ Million)

Figure 15 Localized: Global Scleroderma Therapeutics Market Value, 2017-2027 ($ Million)

Figure 16 Global Scleroderma Therapeutics Market Y-o-Y Growth, By Distribution Channel, 2018-2027 (%)

Figure 17 Retail Stores: Global Scleroderma Therapeutics Market Value, 2017-2027 ($ Million)

Figure 18 Online Stores: Global Scleroderma Therapeutics Market Value, 2017-2027 ($ Million)

Figure 19 Hospitals: Global Scleroderma Therapeutics Market Value, 2017-2027 ($ Million)

Figure 20 Others: Global Scleroderma Therapeutics Market Value, 2017-2027 ($ Million)

Figure 21 North America Scleroderma Therapeutics Market Value, 2017-2027 ($ Million)

Figure 22 North America Scleroderma Therapeutics Market Share, By Drug Class, 2018 & 2027 (%)

Figure 23 North America Scleroderma Therapeutics Market Share, By Indication, 2018 & 2027 (%)

Figure 24 North America Scleroderma Therapeutics Market Share, By Distribution Channel, 2018 & 2027 (%)

Figure 25 South America Scleroderma Therapeutics Market Value, 2017-2027 ($ Million)

Figure 26 South America Scleroderma Therapeutics Market Share, By Drug Class, 2018 & 2027 (%)

Figure 27 South America Scleroderma Therapeutics Market Share, By Indication, 2018 & 2027 (%)

Figure 28 South America Scleroderma Therapeutics Market Share, By Distribution Channel, 2018 & 2027 (%)

Figure 29 Europe Scleroderma Therapeutics Market Value, 2017-2027 ($ Million)

Figure 30 Europe Scleroderma Therapeutics Market Share, By Drug Class, 2018 & 2027 (%)

Figure 31 Europe Scleroderma Therapeutics Market Share, By Indication, 2018 & 2027 (%)

Figure 32 Europe Scleroderma Therapeutics Market Share, By Distribution Channel, 2018 & 2027 (%)

Figure 33 Asia-Pacific Scleroderma Therapeutics Market Value, 2017-2027 ($ Million)

Figure 34 Asia-Pacific Scleroderma Therapeutics Market Share, By Drug Class, 2018 & 2027 (%)

Figure 35 Asia-Pacific Scleroderma Therapeutics Market Share, By Indication, 2018 & 2027 (%)

Figure 36 Asia-Pacific Scleroderma Therapeutics Market Share, By Distribution Channel, 2018 & 2027 (%)

Figure 37 Middle East & Africa Scleroderma Therapeutics Market Value, 2017-2027 ($ Million)

Figure 38 Middle East & Africa Scleroderma Therapeutics Market Share, By Drug Class, 2018 & 2027 (%)

Figure 39 Middle East & Africa Scleroderma Therapeutics Market Share, By Indication, 2018 & 2027 (%)

Figure 40 Middle East & Africa Scleroderma Therapeutics Market Share, By Distribution Channel, 2018 & 2027 (%)

Figure 41 Boehringer Ingelheim International GmbH: Financials

Figure 42 Corbus Pharmaceuticals Holdings, Inc.: Financials

Figure 43 Bayer AG: Financials

Figure 44 Gilead Sciences, Inc.: Financials

Figure 45 Allergan, Inc.: Financials

Figure 46 Pfizer, Inc.: Financials

Figure 47 Sanofi: Financials

Figure 48 GlaxoSmithKline plc: Financials

Figure 49 Cumberland Pharmaceuticals, Inc.: Financials

Figure 50 Actelion Pharmaceuticals, Inc.: Financials

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Get your FREE SAMPLE PROPOSAL with a single click!

linkedinpinterest